Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.29 USD
Change Today -0.01 / -0.43%
Volume 176.7K
AMRS On Other Exchanges
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

amyris inc (AMRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/20/14 - $3.47
52 Week Low
09/1/15 - $1.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMYRIS INC (AMRS)

amyris inc (AMRS) Related Businessweek News

No Related Businessweek News Found

amyris inc (AMRS) Details

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products for the consumer care, specialty chemical, and transportation fuel markets worldwide. The company applies its industrial synthetic biology platform to design microbes and primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and various materials for performance materials market; renewable fuels for transportation fuels market; and base oils for lubricants market. It has a collaboration partnership with Total to commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

419 Employees
Last Reported Date: 08/10/15
Founded in 2003

amyris inc (AMRS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $550.0K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $300.0K
President of Research and Development
Total Annual Compensation: $358.8K
Compensation as of Fiscal Year 2014.

amyris inc (AMRS) Key Developments

Amyris, Inc. and Infectious Disease Research Institute Announce Agreement to Evaluate Adjuvant Formulations

Amyris, Inc. and Infectious Disease Research Institute have announced an agreement to explore testing and development of an Amyris material for use in adjuvant formulations, which reportedly enhance the effectiveness of vaccines. Amyris will provide its materials for testing new adjuvant formulations, and the organizations will work together to explore their use to improve the global supply of important vaccines. Amyris has demonstrated success in creating new ingredients for multiple markets that disrupts the status quo, reduces development cost and speeds product development while providing stable, low-cost supply alternatives. This success has resulted in leading global companies selecting Amyris as a collaboration partner to solve their difficult product development and supply issues.

Amyris, Inc. Announces Multi-Year Technology Investment Agreement with Defense Advanced Research Projects Agency to Create New Research and Development Tools and Technologies

Amyris, Inc. announced a multi-year technology investment agreement worth up to $35 million with the Defense Advanced Research Projects Agency's Biological Technologies Office to create new research and development tools and technologies that will reduce the time and cost of bringing new molecules to market. This agreement will foster the development of new bio-based manufacturing solutions that should position the U.S. as a leader in the development and deployment of biotechnology-based products. The tools and infrastructure developed through DARPA-funded efforts are expected to enable scalable development of transformative defense-relevant products and systems that are currently too complex to access. Amyris will leverage its current and planned infrastructure to generate commercial-scale amounts of hundreds of new molecules of relevance to DARPA's Living Foundries program. These molecules are anticipated to include chemical building blocks for accessing radical new materials that are impossible to create with traditional petroleum-based feed stocks. Beyond the anticipated industry-wide advancements to be made, this effort is expected to expand Amyris's research activities across multiple new organisms, add hundreds of new molecules from multiple pathways to Amyris's production portfolio and integrate several advanced technologies into Amyris's strain improvement pipeline.

Amyris, Inc. Approves an Amendment to Certificate of Incorporation

Amyris, Inc. announced that at the special meeting of stockholders held on September 17, 2015, shareholders of the company approved an amendment to the company's certificate of incorporation to increase the number of total authorized shares from 305,000,000 to 405,000,000 and the number of authorized shares of common stock from 300,000,000 to 400,000,000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMRS:US $2.29 USD -0.01

AMRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China Clean Energy Inc $0.02 USD 0.00
Gevo Inc $2.16 USD +0.02
Methes Energies International Ltd $0.44 USD -0.02
Parabel Inc $0.25 USD 0.00
Solazyme Inc $2.98 USD -0.205
View Industry Companies

Industry Analysis


Industry Average

Valuation AMRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMYRIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at